Scandinavian Prostate Cancer Group

The Scandinavian Prostate Cancer Group (SPCG) is a group of scientific researchers who have conducted a series of clinical trials of treatments for prostate cancer.^[1][2] The group was founded in 1981 and the first study, SPCG-1, began in 1984.^[1]

The studies conducted by the SPCG include the following:^[1][2][3]

• SPCG-1 – estramustine phosphate versus diethylstilbestrol for high-risk advanced prostate cancer^[1][4][5]
• SPCG-2 – orchiectomy plus cyproterone acetate versus placebo for metastatic prostate cancer^[6][7]
• SPCG-3 – cancelled^[1]
• SPCG-4 – radical prostatectomy versus watchful waiting for localized prostate cancer^{[1][8][9][10][11]}
• SPCG-5 – polyestradiol phosphate versus triptorelin or orchiectomy plus flutamide for advanced prostate cancer^{[1][12][13][14][15][16][17]}
• SPCG-6 – bicalutamide monotherapy versus standard care (watchful waiting) for localized prostate cancer^{[1][18][19][20][21][22]}
• SPCG-7 – endocrine therapy with versus without radiotherapy for locally advanced or aggressive localized prostate cancer^[23][24][25]
• SPCG-8 – cancelled^[1]
• SPCG-9 – cancelled^[1]
• SPCG-10 – cancelled^[1][26]
• SPCG-11 (Zometa European Study [ZEUS]) – zoledronic acid with standard prostate cancer therapy versus standard prostate cancer therapy alone for prevention of bone metastases in high-risk localized prostate cancer^{[3][27][28][29]}
• SPCG-12 – docetaxel versus surveillance after radical prostatectomy without androgen deprivation therapy for high-risk localized prostate cancer^[3][30][31]
• SPCG-13 – docetaxel versus surveillance after radical prostatectomy with androgen deprivation therapy for high-risk localized prostate cancer^[3][32]
• SPCG-14 – docetaxel versus bicalutamide for prostate-specific antigen recurrence after radical prostatectomy or radiotherapy for localized prostate cancer^[3][33]
• SPCG-15 – radical prostatectomy versus radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer^[3][34]

The SPCG-6 study was also known as Trial 25 of the Early Prostate Cancer (EPC) clinical trial programme.^{[35][18][19][20][21]}

The SPCG also published a 1997 literature review on combined androgen blockade for advanced prostate cancer.^[36]

• FinnProstate Group